WO2008045272A3 - Compositions and methods for skin lightening - Google Patents

Compositions and methods for skin lightening Download PDF

Info

Publication number
WO2008045272A3
WO2008045272A3 PCT/US2007/021288 US2007021288W WO2008045272A3 WO 2008045272 A3 WO2008045272 A3 WO 2008045272A3 US 2007021288 W US2007021288 W US 2007021288W WO 2008045272 A3 WO2008045272 A3 WO 2008045272A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
skin
compositions
mammal
skin lightening
Prior art date
Application number
PCT/US2007/021288
Other languages
French (fr)
Other versions
WO2008045272A2 (en
Inventor
Annette Tobia
Michael Schwartz
Alice Marcy
Original Assignee
Dynamis Therapeutics Inc
Annette Tobia
Michael Schwartz
Alice Marcy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynamis Therapeutics Inc, Annette Tobia, Michael Schwartz, Alice Marcy filed Critical Dynamis Therapeutics Inc
Publication of WO2008045272A2 publication Critical patent/WO2008045272A2/en
Publication of WO2008045272A3 publication Critical patent/WO2008045272A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Abstract

The invention relates to compounds and methods for inhibiting production and function of tyrosinase in the skin of a mammal. The invention further relates to compounds and methods for inhibiting darkening of the skin of a mammal, as well as lightening the skin of a mammal and reducing pigmentation in the skin of a mammal.
PCT/US2007/021288 2006-10-06 2007-10-04 Compositions and methods for skin lightening WO2008045272A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85023106P 2006-10-06 2006-10-06
US60/850,231 2006-10-06

Publications (2)

Publication Number Publication Date
WO2008045272A2 WO2008045272A2 (en) 2008-04-17
WO2008045272A3 true WO2008045272A3 (en) 2008-06-19

Family

ID=39283355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/021288 WO2008045272A2 (en) 2006-10-06 2007-10-04 Compositions and methods for skin lightening

Country Status (2)

Country Link
TW (1) TW200817039A (en)
WO (1) WO2008045272A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
EP2228050A1 (en) * 2009-03-09 2010-09-15 Marcel Cohen Use of gamma-aminobutyric acid as a depigmenting agent
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
RS62540B1 (en) 2010-08-05 2021-12-31 Forsight Vision4 Inc Apparatus to treat an eye
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
TWI566772B (en) * 2011-04-12 2017-01-21 資生堂股份有限公司 Whitening agent and malanin production inhibitor
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
FR2979237B1 (en) * 2011-08-23 2013-08-16 Oreal METHOD OF DEPIGMENTING THE SKIN
WO2013040247A2 (en) 2011-09-16 2013-03-21 Forsight Vision4, Inc. Fluid exchange apparatus and methods
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
EP3158995B1 (en) * 2012-08-09 2018-05-23 Dynamis Therapeutics, Inc. Meglumine for reducing high triglyceride levels
CA2905496A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
AU2014241163B2 (en) 2013-03-28 2018-09-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
WO2016011191A1 (en) 2014-07-15 2016-01-21 Forsight Vision4, Inc. Ocular implant delivery device and method
SG11201700943TA (en) 2014-08-08 2017-03-30 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CA2967330A1 (en) 2014-11-10 2016-05-19 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
CN113069681B (en) 2015-11-20 2022-12-23 弗赛特影像4股份有限公司 Method of manufacturing a therapeutic device for sustained drug delivery
ES2837524T3 (en) 2016-04-05 2021-06-30 Forsight Vision4 Inc Implantable ocular drug delivery devices
CN111655206B (en) 2017-11-21 2022-10-14 弗赛特影像4股份有限公司 Fluid exchange device for expandable port delivery system and method of use
FR3123193A1 (en) 2021-05-28 2022-12-02 L'oreal Electroporation process for delivering a composition comprising at least one peptide of molecular weight ranging from 500 Da to 20 kDa
FR3123192A1 (en) 2021-05-28 2022-12-02 L'oreal Electroporation method for delivering a composition comprising at least one hydroxy acid compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6219575B1 (en) * 1998-10-23 2001-04-17 Babak Nemati Method and apparatus to enhance optical transparency of biological tissues
US6653315B2 (en) * 2001-10-15 2003-11-25 Schering Corporation Adenosine A2a receptor antagonists
US20040265252A1 (en) * 2003-04-11 2004-12-30 New York University Compounds stimulating and inhibiting melanin formation, and methods for screening these compounds
US20060110439A1 (en) * 2004-10-22 2006-05-25 Dynamis Therapeutics, Inc. Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6219575B1 (en) * 1998-10-23 2001-04-17 Babak Nemati Method and apparatus to enhance optical transparency of biological tissues
US6653315B2 (en) * 2001-10-15 2003-11-25 Schering Corporation Adenosine A2a receptor antagonists
US20040265252A1 (en) * 2003-04-11 2004-12-30 New York University Compounds stimulating and inhibiting melanin formation, and methods for screening these compounds
US20060110439A1 (en) * 2004-10-22 2006-05-25 Dynamis Therapeutics, Inc. Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATTILA ET AL.: "Effects of a Long-Term Dietary Xylitol Supplementation on Collagen Content and Fluorescence of the Skin in Aged Rats", GERONTOLOGY, vol. 51, no. 3, 2005, pages 166 - 169 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery

Also Published As

Publication number Publication date
WO2008045272A2 (en) 2008-04-17
TW200817039A (en) 2008-04-16

Similar Documents

Publication Publication Date Title
WO2008045272A3 (en) Compositions and methods for skin lightening
WO2007093627A3 (en) Biocidal composition
WO2010005989A8 (en) Dermatological compositions with anti-aging and skin even-toning properties
ZA201006732B (en) 2-aza-bicyclo[2.2.1]heptane derivatives
WO2009135857A3 (en) Polyurethanes as rheological modifying means for cosmetic preparations
WO2011059866A3 (en) Composition and methods for improving skin appearance
WO2006136357A3 (en) Crystalline modifications to pyraclostrobin
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008070616A3 (en) METHODS AND COMPOSITIONS RELATED TO HIF-1α
WO2008017079A3 (en) Dyes and precursors and conjugates thereof
WO2010118866A8 (en) Trehalulose-containing composition, its preparation and use
WO2009007532A3 (en) Use of a haemoglobin for the preparation of dressings and resulting dressings
ZA200807944B (en) Skin lightening agents, compositions and methods
WO2009051460A3 (en) Peptide coupled ascorbic acid derivatives
ZA201104223B (en) Skin lightening compositions with acetylcholinesterase inhibitors
WO2010072787A3 (en) A composition comprising a retinoid and method of treating skin conditions
ZA200807945B (en) Skin lightening agents, compositions and methods
WO2007144521A3 (en) Cosmetic composition for topical use comprising wasabi
ZA201100108B (en) Skin lightening compositions comprising co2 extracts
EP2303010A4 (en) A composition for improving skin condition and appearance
HK1126959A1 (en) Skin-whitening agent for external application to the skin, and method for whitening the skin
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
EP2061493A4 (en) Compositions to reduce or prevent skin cancer
WO2010130776A3 (en) Use of delta-tocopheryl-carbohydrate as a depigmenting agent
PL385075A1 (en) method of production of cement and hydraulic binding agent as well as the cement and hydraulic binding agent, and method to upgrade class of cement and application of cement

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07839230

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07839230

Country of ref document: EP

Kind code of ref document: A2